+1-518-618-1030 866 - 552 - 3453 USA-Canada Toll Free
Published Date: 2017-12-04Number of Pages: 161

Myasthenia Gravis Market (Treatment- Drug Treatment (Cholinesterase Inhibitors, Monoclonal Antibodies, and Chronic Immunomodulators) and Rapid Immunotherapies (Plasmapheresis, Intravenous Immunoglobulin (IVlg), and Thymectomy)) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 - 2025

Global Myasthenia Gravis Market: Snapshot

The global myasthenia gravis market is treading a growth path owing to the need to prevent deterioration of quality of life due to myasthenia gravis. Myasthenia gravis is an autoimmune disorder and neuromuscular disorder that causes weakness of muscles. The condition is characterized by fatigue and weakness of skeletal muscles. Muscles that monitor swallowing and breathing, eye movement, eye lids, and shoulder and facial muscles are the ones that are usually impacted in myasthenia gravis.

The growth of myasthenia gravis market is also driven by research and development initiatives for novel therapeutics. Key players in the market are also engaged in research to launch affordable therapeutics for myasthenia gravis.

A report by Transparency Market Research (TMR) projects the global myasthenia gravis market to become worth US$2,313.1 mn by 2025 from US$975.1 mn in 2016 at a CAGR of 10.1% therein.

global myasthenia gravis market

Rising Acceptance of Robotic-assisted Therapeutics to Benefit Thymectomy Treatment Segment

The report studies the global myasthenia gravis market on the basis of treatment and geography. The key treatment segments include drug treatment, rapid immunotherapies, and thymectomy. The drug treatment segment is sub-segmented into cholinesterase inhibitors, monoclonal antibodies, and chronic Immunomodulators. The rapid immunotherapies segment is categorized into plasmapheresis and intravenous immunoglobulin. The cholinesterase inhibitors within drug treatment sub-segment blocks the breakdown of acetylcholine which acts as a neurotransmitter in both central and peripheral nervous system.

On the other hand, chronic immunomodulators within drug treatment segment are chemical agents which are responsible for modifying the immune response of the immune system by inhibition of white blood cell activity.

The plasmapheresis sub-segment within rapid immunotherapies segment involves removal, treatment, or exchange of blood plasma or components for myasthenia gravis. The duration of the treatment usually lasts from one to three hours. The removal of plasma provides relief from symptoms of muscle weakness. The process involves selective removal of patient’s plasma by means of specific intravenous fluids.

On the other hand, intravenous immunoglobulin involves administering a mixture of antibodies to treat a number of health conditions such as myasthenia gravis. Some of the functions of immunoglobulin involve multiple activities such as suppression of idiotypic antibodies, metalloproteinase, and various inflammatory mediators.

Thymectomy accounts as an important constituent for the treatment of myasthenia gravis. With the rising acceptance of minimally invasive thymectomy, the growth of robotic-assisted techniques is on the rise.

Asia Pacific to Emerge as Key Region in Future

The global myasthenia gravis market on the basis of geography has been segmented into North America, Asia Pacific, Europe, Latin America, and the Middle East and Africa. Among them, North America is a key market for myasthenia gravis. According to statistics of Center for Disease Control & Prevention, the prevalence of myasthenia gravis is estimated to be from 14 to 20 per 100,000 population in the United States.

Europe follows North America in terms of revenue contribution to the global myasthenia gravis market. This is mainly because of a growing geriatric population and increasing prevalence of myasthenia gravis.

Asia Pacific, Latin America, and the Middle East and Africa are largely untapped market for myasthenia gravis. Asia Pacific is likely to display leading growth rate among other key regions for myasthenia gravis over the forecast period. Several governmental and non-governmental organizations in the region are involved in organizing awareness programs which is expected to propel the myasthenia gravis market in the region.

Key players in the global myasthenia gravis market include Alexion Pharmaceutical Inc., Avadel Pharmaceuticals plc, CSL Behring, Grifols S.A., Baxter International Inc., Shire plc, Novartis AG, F. Hoffmann-La Roche AG, Takeda Pharmaceutical Company Limited, and Valeant Pharmaceuticals International Inc.

Global Myasthenia Gravis Market: Overview

Myasthenia gravis is a chronic, debilitating and neuromuscular autoimmune disease that can take place at any time of life but most often starts for men after the age of 55 and women around the age of 40. Most of patients with generalized myasthenia gravis possible and can be managed with present therapies for myasthenia gravis, 10-15% of patients fail to respond tolerably to or cannot bear multiple therapies for myasthenia gravis and continue to suffer deep muscle weakness, and severe disease symptoms that limits function. As there is lack of targeted therapy in myasthenia gravis management, use of monoclonal antibodies in treatment myasthenia gravis is likely to give paradigm shift in myasthenia gravis market. Rituximab is another monoclonal antibody therapeutic agent which is currently under clinical trials for myasthenia gravis management.

A detailed overview of market dynamics, including the drivers, restraints, and opportunities of the myasthenia gravis market, along with porter’s analysis, regulatory scenario for myasthenia gravis treatment, pipeline assessment for upcoming treatment options for myasthenia gravis, and market strategies adopted by top players of the global myasthenia gravis market, has been provided in this report. Market revenue analysis for all the above mentioned segments has been provided for the forecast period of 2017-2025, considering 2016 as the base year, and 2015 as the historical year, along with compound annual growth rate (CAGR %) for the forecast period of 2017-2025. Market share estimations were based on in-depth analysis and study of products, and their features etc.

This report provides in-depth analysis value of the myasthenia gravis market. The stakeholders for this report include companies involved in the manufacturing of heparin. Executive summary section is included snapshot on stakeholders in this report, which summarizes the market size, trends and competition in different regions. Market players and Market share analysis is analyzed to signify percentage share of the major players operating in the myasthenia gravis market. Furthermore, the report includes market analysis by geography that depicts the most attractive and significant region in the global market in 2016.

Global Myasthenia Gravis Market: Research Methodology

The research methodology is a combination of primary and secondary research. Primary research includes information collected via e-mails, and telephonic interviews of key opinion leaders (KOL), and forms the bulk of our research. Secondary research includes information collected from various sources, by study of company websites, annual reports, stock analysis presentations, press releases, and various national and international databases.  

Global Myasthenia Gravis Market: Market Segmentation

On the basis of treatment type global myasthenia gravis market is segmented into drug treatment, rapid immunotherapies, and Thymectomy. Moreover, drug treatment segment further categorized into cholinesterase inhibitors, chronic immune-modulators, and monoclonal antibodies. Where rapid immunotherapies are segmented into plasmapheresis, and intravenous immunoglobulin (IvIg). Based on geography, the market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The report also consist of overall myasthenia gravis market analysis for countries such as U.S., Canada, Germany, U.K., France, Italy, Spain, China, India, Japan, Australia & New Zealand, Brazil, Mexico, GCC Countries, and South Africa Myasthenia Gravis market for all treatment types.

Global Myasthenia Gravis Market: Competitive Landscape

The report also comprises list of major players in the market, their SWOT analysis, market share of these players in the myasthenia gravis market, key business strategies, product portfolios, and recent developments. Key market players profiled in this report include, Alexion Pharmaceutical Inc., Avadel Pharmaceuticals, PLC. (Flamel Technologies), CSL Behring, Grifols, S.A., Baxter International, Inc., Shire plc, Novartis AG, F. Hoffmann-La Roche AG, Takeda Pharmaceutical Company Limited, and Valeant Pharmaceuticals International, Inc.

The global myasthenia gravis market has been segmented as follows:

Global Myasthenia Gravis Market, by Treatment

  • Drug Treatment
    • Cholinesterase Inhibitors
    • Chronic Immunomodulators
    • Monoclonal Antibodies
  • Rapid Immunotherapies
    • Plasmapheresis
    • Intravenous Immunoglobulin (Ivlg)
    • Thymectomy

 Global Myasthenia Gravis Market, by Geography

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa


 
 
Back To Top